Anti-Müllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors.

Autor: Nakhuda GS; Columbia University College of Physicians and Surgeons, Division of Reproductive Endocrinology and Infertility, Centre for Women's Reproductive Care, New York, NY 10019, USA. gsn16@columbia.edu, Douglas NC, Thornton MH, Guarnaccia MM, Lobo R, Sauer MV
Jazyk: angličtina
Zdroj: Reproductive biomedicine online [Reprod Biomed Online] 2011 Feb; Vol. 22 Suppl 1, pp. S88-93.
DOI: 10.1016/S1472-6483(11)60014-X
Abstrakt: While the age of a donor is a fundamental factor to the success of donor IVF, no serum markers have been demonstrated to be useful in predicting variability of ovarian response in individual donors. Anti-Müllerian hormone (AMH) has been described as an accurate marker of ovarian response in patients undergoing IVF, but has not been applied to oocyte donors. AMH concentrations from 104 anonymous oocyte donors between the ages of 21-32 years were studied and IVF outcome parameters compared. AMH was correlated with several parameters including the number of oocytes retrieved (r = 0.232, P = 0.024), the peak oestradiol concentrations (r = 0.235, P = 0.024) and the need to decrease gonadotrophin dose in order to avoid ovarian hyperstimulation syndrome (r = 0.274, P = 0.007). Receiver operating curve analysis was able to identify an AMH threshold that rendered about 70% sensitivity and 70% specificity for predicting the need to decrease gonadotrophin dosing. The clinical pregnancy rate was 77% per recipient and was not related to the donors' AMH concentrations. For oocyte donors, measurement of AMH appears most useful for determining gonadotrophin sensitivity in order to mitigate symptoms consistent with ovarian hyperstimulation.
(Copyright © 2011 Reproductive Healthcare Ltd. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: